Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on PK of BPI-16350 in Healthy Volunteers
NCT05316259Phase 1Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tibremciclib in breast cancer and solid tumor, sponsored by Betta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Timepoint and 1 more. Started Apr 2022; status: completed.
02
Drugs
tibremciclib
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT05316259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316259.